<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422175</url>
  </required_header>
  <id_info>
    <org_study_id>CBAF312A2101</org_study_id>
    <nct_id>NCT00422175</nct_id>
  </id_info>
  <brief_title>Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312</brief_title>
  <official_title>A First-in-Human Study for BAF312: A Two Parts, Single Center, Randomized, Double-Blind, Placebo-Controlled Ascending Single Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral BAF312 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and effect of oral BAF312 on
      bodily functions as well as the body's absorption, distribution, metabolism, and excretion of
      BAF312 in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety, tolerability, and pharmacokinetic profile</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte counts and lymphocyte recovery period</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac rate and rhythm</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
  </secondary_outcome>
  <enrollment>63</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAF 312</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects, 18 to 55 years of age included, and in good health

          -  Female subjects must be either surgically sterilized at least 6 months prior to study
             participation or post-menopausal (no regular menstrual bleeding for at least 1 years)

          -  Female subjects test are required to have a negative result for a pregnancy test, not
             be lactating/breast feeding, and must either:

          -  Body mass index (BMI) must be within the range of 18 to 30 Kg/m2. Subjects must weigh
             at least 50 kg to participate in this study.

          -  Able to communicate with the investigator, to understand and comply with the
             requirements of the study

          -  Understand and sign the written informed consent firm

        Exclusion Criteria:

          -  Smokers

          -  Subjects who received live vaccine 4 weeks prior to dosing.

          -  Use of any prescription drugs four weeks prior dosing, or over-the-counter (OTC)
             medication (vitamins, herbal supplements, dietary supplements) within two weeks prior
             to dosing. Acetaminophen is acceptable

          -  Participation in any clinical investigation within 4 weeks prior to dosing or longer
             if required by local regulations, and for any other limitation of participation based
             on local regulations.

          -  Donation or loss of 400 ml or more of blood within 8 weeks prior to first dosing, or
             longer if required by local regulation.

          -  Significant illness within two weeks prior to dosing.

          -  A past personal or close family medical history of clinically significant cardiac
             abnormalities

          -  History of Acute or chronic bronchospastic disease (including asthma and chronic
             obstructive pulmonary disease) Clinically significant drug allergy or history of
             atopic allergy (asthma, urticaria, eczematous dermatitis) Known hypersensitivity or
             severe adverse event to darifenacin or similar drugs Any surgical or medical condition
             which might significantly alter the absorption, distribution, metabolism or excretion
             of drugs or which may jeopardize participation in the study Immunodeficiency diseases,
             including a positive HIV (ELISA and Western blot) test result Positive Hepatitis B
             surface antigen (HBsAg) or Hepatitis C test result. Drug or alcohol abuse

        Additional protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigative site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2007</study_first_submitted>
  <study_first_submitted_qc>January 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2007</study_first_posted>
  <last_update_submitted>November 28, 2007</last_update_submitted>
  <last_update_submitted_qc>November 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2007</last_update_posted>
  <keyword>Safety, tolerability, pharmacokinetics, pharmacodynamics, oral, BAF312, healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

